Skip to main content

Table 4 Summary of the adverse events reported by two or more subjects in the single oral dose study

From: Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study

  

GSK2239633

  
 

Placebo (n = 24) n (%)

150 mg (n = 8) n (%)

300 mg (n = 8) n (%)

600 mg (n = 8) n (%)

900 mg (n = 8) n (%)

1200 mg (n = 8) n (%)

1500 mg (n = 8) n (%)

1200 mg (Fed) (n = 8) n (%)

Placebo (Fed) (n = 4) n (%)

Total (n = 24) n (%)

Any event

9 (38)

4 (50)

5 (63)

5 (63)

1 (13)

2 (25)

3 (38)

2 (25)

1 (25)

19 (79)

Headache

3 (13)

2 (25)

0

0

1 (13)

1 (13)

1 (13)

0

0

5 (21)

Diarrhoea

2 (8)

0

2 (25)

1 (13)

1 (13)

0

2 (25)

0

0

4 (17)

Rhinitis

1 (4)

1 (13)

0

0

0

0

1 (13)

0

0

2 (8)

Abdominal pain

0

0

0

0

0

0

1 (13)

0

0

1 (4)